Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Prescribe Right Pharmaceutical Pipeline Update for August 9

8/9/2018

 
Eleven Items of Interest from over 200 Informational feeds from around the Pharmaceutical industry.
  • The FDA approved Progenics Pharmaceuticals’ iobenguane I 131 for the treatment of pheochromocytoma or paraganglioma on July 30, 2018.
  • The FDA approved Shionogi’s lusutrombopag (Brand name: Mulpletaon) on July 31, 2018, for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
  • Quizartinib (Ambit Biosciences Corporation, Daiichi Sankyo) was awarded Breakthrough status by the FDA.
  • In a 40-patient, Phase II trial, treatment with apatinib (by Jiangsu Chiatai Qingjiang & Advenchen) resulted in a PFS of 3 months and overall survival of 7.7 months in heavily pretreated patients with advanced non-squamous non-small-cell lung cancer. Also, in a 437-patient, Phase III trial, anlotinib improved overall survival versus placebo in pretreated patients with advanced NSCLC. An analysis of this same patient population found that anlotinib improved quality of life compared to placebo.
  • In a 24-week, 314 patient, Phase II trial, patients treated with baricitinib (Lilly, Incyte) 4mg had a resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000, compared to placebo in patients with systemic lupus erythematosus. The 2mg dose failed to show an improvement compared to placebo.
  • Redhill announced that in a 26-week, 331 patient, Phase III trial, treatment with RHB-104 resulted in 37% of patients achieving compared to 23% with placebo in patients with Crohn’s disease. However, at 52 weeks the results were no longer statistically significant (27% for RHB-104 vs 20% for placebo).
  • Active Biotech announced that in a 12-month, 331 patient, Phase II trial, laquinimod did not improve the Unified Huntington's Disease Rating Scale - Total Motor Score compared to placebo.
  • Otsuka announced that in the 815 patient, Phase III, ASTRAL-1 trial, guadecitabine did not improve the complete response or overall survival rates compared to azacitidine, decitabine or low-dose cytarabine in treatment naive patients with acute myeloid leukemia.
  • Astex is assessing guadecitabine in the ongoing Phase III ASTRAL-2 (acute myeloid leukemia) and ASTRAL-3 (myelodysplastic syndromes and chronic myelomonocytic leukemia) trials.
  • Nektar has submitted an NDA for NKTR-181 with a PDUFA date of May 28, 2019.
  • Conatus announced that in a 3-month, 74 patient, Phase II trial, patients that received emricasan had similar MELD scores, INRs and total bilirubin compared to placebo in patients with cirrhosis. A reduction in MELD score, INR and total bilirubin compared to placebo was seen in 9 patients with MELD scores of 15 or higher.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.